




Instance: composition-en-e8ab7070a1e099803634040c1dcebc5b
InstanceOf: CompositionUvEpi
Title: "Composition for miglustat Package Leaflet"
Description:  "Composition for miglustat Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "EU/1/17/1232/001"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mpe8ab7070a1e099803634040c1dcebc5b)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - miglustat"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional

  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>unavailable</div>"""
  * emptyReason = http://terminology.hl7.org/CodeSystem/list-empty-reason#unavailable   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>unavailable</div>"""
  * emptyReason = http://terminology.hl7.org/CodeSystem/list-empty-reason#unavailable   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet</p>
<ol>
<li>What Miglustat Gen.Orph is and what it is used for  </li>
<li>What you need to know before you take Miglustat Gen.Orph </li>
<li>How to take Miglustat Gen.Orph </li>
<li>Possible side effects  </li>
<li>How to store Miglustat Gen.Orph </li>
<li>Contents of the pack and other information </li>
</ol> </div>"""   
          

* section[=].section[+]
  * title =  "1. What miglustat is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What miglustat is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Miglustat Gen.Orph contains the active substance miglustat which belongs to a group of medicines 
that affect metabolism. It is used to treat two conditions: </p>
<ul>
<li>Miglustat Gen.Orph is used to treat mild to moderate type 1 Gaucher disease in adults. </li>
</ul>
<p>In type 1 Gaucher disease, a substance called glucosylceramide is not removed from your body. It 
starts to build up in certain cells of the body s immune system. This can result in liver and spleen 
enlargement, changes in the blood and bone disease. </p>
<p>The usual treatment for type 1 Gaucher disease is enzyme replacement therapy. Miglustat Gen.Orph is 
only used when a patient is considered unsuitable for treatment with enzyme replacement therapy. </p>
<ul>
<li>Miglustat Gen.Orph is also used to treat progressive neurological symptoms in Niemann-
Pick type C disease in adults and in children. </li>
</ul>
<p>If you have Niemann-Pick type C disease, fats such as glycosphingolipids build up in the cells of your 
brain. This can result in disturbances in neurological functions such as slow eye movements, balance, 
swallowing, and memory, and in seizures. </p>
<p>Miglustat Gen.Orph works by inhibiting the enzyme called  glucosylceramide synthase  which is 
responsible for the first step in the synthesis of most glycosphingolipids. </p> </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take miglustat"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take miglustat"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Do not take Miglustat Gen.Orph 
- if you are allergic to miglustat or any of the other ingredients of this medicine<br />
(listed in section 6) </p>
<p>Warnings and precautions<br />
Talk to your doctor or pharmacist before taking Miglustat Gen.Orph 
- if you suffer from kidney disease 
- if you suffer from liver disease </p>
<p>Your doctor will perform the following tests before treatment and during treatment with Miglustat 
Gen.Orph:</p>
<ul>
<li>an examination to check the nerves in your arms and legs </li>
<li>measurement of vitamin B12 levels </li>
<li>monitoring growth if you are a child or adolescent with Niemann-Pick type C disease </li>
<li>monitoring of blood platelet counts </li>
</ul>
<p>The reason for these tests is that some patients have had tingling or numbness in the hands and feet, or 
a decrease in body weight, while taking Miglustat Gen.Orph. The tests will help the doctor decide 
whether these effects are due to your disease or other existing conditions, or due to side effects of 
Miglustat Gen.Orph (see section 4 for further details). </p>
<p>If you have diarrhoea, your doctor may ask you to change your diet to reduce your lactose and 
carbohydrate intake such as sucrose (cane sugar), or not to take Miglustat Gen.Orph together with 
food, or to temporarily reduce your dose. In some cases the doctor may prescribe anti-diarrhoeal 
medicines such as loperamide. If your diarrhoea does not respond to these measures, or if you have 
any other abdominal complaint, consult your doctor. In such case, your doctor may decide to conduct 
further investigations. </p>
<p>Male patients should use reliable birth control methods during their treatment with Miglustat 
Gen.Orph, and for 3 months after finishing treatment. </p>
<p>Children and adolescents 
Do not give this medicine to children and adolescents (below 18 years old) with type 1 Gaucher 
disease because it is not known if it works in this disease. </p>
<p>Other medicines and Miglustat Gen.Orph 
Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other 
medicines. </p>
<p>Tell your doctor if you are taking medicines containing imiglucerase, which are sometimes used at the 
same time as Miglustat Gen.Orph. They may lower the amount of Miglustat Gen.Orph in your body. </p>
<p>Pregnancy, breast-feeding and fertility 
You should  not take Miglustat Gen.Orph if you are pregnant or thinking of becoming pregnant. Your 
doctor can give you more information. You must use effective birth control while taking Miglustat 
Gen.Orph. Do not breastfeed while you are taking Miglustat Gen.Orph. </p>
<p>Male patients should use reliable birth control methods during their treatment with Miglustat 
Gen.Orph, and for 3 months after finishing treatment. </p>
<p>If you are pregnant, breast feeding, think you may be pregnant or planning to have a baby, ask your 
doctor or pharmacist for advice before taking this medicine. </p>
<p>Driving and using machines 
Miglustat Gen.Orph may make you feel dizzy. Do not drive or use any tools or machines if you feel 
dizzy. </p>
<p>Miglustat Gen.Orph contains sodium 
This medicine contains less than 1 mmol sodium (23 mg) per hard capsule, that is to say essentially 
'sodium-free'. </p> </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take miglustat"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take miglustat"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist 
if you are not sure. </p>
<ul>
<li>
<p>For type 1 Gaucher disease: for adults, the usual dose is one capsule (100 mg) three times a 
day (morning, afternoon and evening). This means a daily maximum of three capsules 
(300 mg). </p>
</li>
<li>
<p>For Niemann-Pick type C disease: For adults and adolescents (over 12 years old), the usual 
dose is two capsules (200 mg) three times a day (morning, afternoon and evening). This means a 
daily maximum of six capsules (600 mg). </p>
</li>
</ul>
<p>For children less than 12 years old, your doctor will adjust the dose for Niemann-Pick type C disease. </p>
<p>If you have a problem with your kidneys you may receive a lower starting dose. Your doctor may 
reduce your dose, e.g., to one capsule (100 mg) once or twice a day, if you suffer from diarrhoea when 
taking Miglustat Gen.Orph (see section 4). Your doctor will tell you how long your treatment will last. </p>
<p>Miglustat Gen.Orph can be taken with or without food. You should swallow the whole capsule with a 
glass of water. </p>
<p>If you take more Miglustat Gen.Orph than you should 
If you take more capsules than you were told to, consult your doctor immediately. Miglustat has been 
used in clinical studies at doses up to 3000 mg: this caused decreases in white blood cells and other 
side effects similar to those described in section 4. If you forget to take Miglustat Gen.Orph 
Take the next capsule at the usual time. Do not take a double dose to make up for a forgotten dose. </p>
<p>If you stop taking Miglustat Gen.Orph 
Don t stop taking Miglustat Gen.Orph without talking to your doctor. 
If you have any further questions on the use of this medicine, ask your doctor or pharmacist. </p> </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. </p>
<p>Most serious side effects: 
Some patients have had tingling or numbness in the hands and feet (seen commonly). They could 
be signs of peripheral neuropathy, due to side effects of Miglustat Gen.Orph or they could be due to 
existing conditions. Your doctor will perform some tests before and during treatment with Miglustat 
Gen.Orph to assess this (see section 2). </p>
<p>If you do get any of these effects, please seek medical advice from your doctor as soon as 
possible. </p>
<p>If you get a slight tremor, usually trembling hands, seek medical advice from your doctor as soon 
as possible. The tremor often disappears without needing to stop the treatment. Sometimes your doctor 
will need to reduce the dose or stop Miglustat Gen.Orph treatment to stop the tremor. </p>
<p>Very common effects (may affect more than 1 in 10 people) 
The most common side effects are diarrhoea, flatulence (wind),  abdominal (stomach) pain, weight loss 
and decreased appetite. </p>
<p>If you do lose some weight when you start treatment with Miglustat Gen.Orph don t worry. People 
usually stop losing weight as treatment goes on. </p>
<p>Common effects (may affect up to 1 in 10 people) 
Common side effects of treatment include headache, dizziness, paraesthesia (tingling or numbness), 
abnormal coordination, hypoaesthesia (reduced sensation to touch), dyspepsia (heartburn), nausea 
(feeling sick), constipation and vomiting, swelling or discomfort in the abdomen (stomach) and 
thrombocytopenia (reduced levels of blood platelets). The neurological symptoms and 
thrombocytopenia could be due to the underlying disease. </p>
<p>Other possible side effects are muscular spasms or weakness, fatigue, chills and malaise, depression, 
difficulty sleeping, forgetfulness and less libido. </p>
<p>Most patients get one or more of these side effects, usually at the start of treatment or at intervals 
during treatment. Most cases are mild and disappear quite quickly. If any of these side effects cause 
problems, consult your doctor. He or she may reduce the dose of Miglustat Gen.Orph or recommend 
other medicines to help control side effects. </p>
<p>Reporting of side effects 
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects 
not listed in this leaflet. You can also report side effects directly via the national reporting system 
listed in Appendix V. By reporting side effects you can help provide more information on the safety of 
this medicine. </p> </div>"""      
        
* section[=].section[+]
  * title = "5. How to store miglustat"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store miglustat"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children. </p>
<p>Do not take this medicine after the expiry date which is stated on the carton after  EXP . The expiry 
date refers to the last day of that month. </p>
<p>This medicine does not require any special storage conditions. </p>
<p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to 
throw away medicines you no longer use. These measures will help protect the environment. </p> </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Miglustat Gen.Orph contains<br />
- The active substance is miglustat 100 mg. 
- The other ingredients are sodium starch glycolate (type A), povidone (K30), magnesium 
stearate, gelatin, titanium dioxide (E171). See section 2  Miglustat Gen.Orph contains sodium . </p>
<p>What Miglustat Gen.Orph looks like and contents of the pack 
Miglustat Gen.Orph 100 mg hard capsules are white opaque cap and body, hard gelatin capsules size 
4 of 14 mm length. 
Pack size of 84 hard capsules in non-perforated blisters and 84x1 hard capsules in perforated unit dose 
blisters. </p>
<p>Not all pack sizes may be marketed. </p>
<p>Marketing Authorisation Holder<br />
Gen.Orph 
185 Bureaux de la Colline 
92213 Saint Cloud Cedex 
France </p>
<p>Manufacturers 
Delpharm Reims 
10 rue Colonel Charbonneaux 
51100 Reims 
France 
or 
Centre Lab 
ZA Granderaie 
23000 Gu ret 
France </p>
<p>For any information about this medicine, please contact the local representative of the Marketing 
Authorisation Holder. </p>
<p>Belgi /Belgique/Belgien<br />
Gen.Orph<br />
T l/Tel: +32 (0)496 85 87 e-mail: reg@studiopharma.be </p>
<p>Lietuva<br />
Gen.Orph 
Tel: +33 (0)1 47 71 04 e-mail: contact@gen-orph.com </p>
<p>.: +359 2 807 50  -mail: diacommerce@diacommerce.bg </p>
<p>Luxembourg/Luxemburg<br />
Gen.Orph 
T l/Tel.: +33 (0)1 47 71 04 email: contact@gen-orph.com </p>
<p>esk  republika<br />
Gen. Orph 
Tel: +33 (0)1 47 71 04 e-mail: contact@gen-orph.com 
Magyarorsz g<br />
Gen.Orph 
Tel.: +33 (0)1 47 71 04 e-mail: contact@gen-orph.com </p>
<p>Danmark<br />
Gen.Orph 
Tlf: +46 (0)8 21 54 e-mail: 
pharmacovigilance.SE@propharmagroup.com </p>
<p>Malta<br />
Gen.Orph 
Tel: +33 (0)1 47 71 04 e-mail: contact@gen-orph.com 
Deutschland<br />
Gen.Orph 
Tel: +49 30 8560687email: 
pharmacovigilance.DE@propharmagroup.com </p>
<p>Nederland<br />
Gen.Orph 
Tel: +32 (0)496 85 87 e-mail : reg@studiopharma.be 
Eesti<br />
Gen.Orph 
Tel: +33 (0)1 47 71 04 email: contact@gen-orph.com </p>
<p>Norge<br />
Gen.Orph 
Tlf: +46 (0)8 21 54 e-mail: pharmacovigilance.SE@propharmagroup.com </p>
<p>Gen.Orph 
 : +33 (0)1 47 71 04 email: contact@gen-orph.com </p>
<p>sterreich<br />
Gen.Orph 
Tel : +33 (0)1 47 71 04 e-mail : contact@gen-orph.com </p>
<p>Espa a<br />
Pharma International S.A. 
Tel: +34 915 635 e-mail: farmacovigilancia@pharmaintl.net </p>
<p>Polska<br />
Gen.Orph 
Tel.: +33 (0)1 47 71 04 e-mail: contact@gen-orph.com </p>
<p>France<br />
Gen.Orph 
Portugal<br />
Biojam, S.A. 
T l.: +33 (0)1 47 71 04 e-mail : contact@gen-orph.com </p>
<p>Tel:  +351 212 697 e-mail:  farmacovigilancia@phagecon.pt </p>
<p>Hrvatska<br />
Gen.Orph 
Tel: +33 (0)1 47 71 04 e-mail: contact@gen-orph.com </p>
<p>Rom nia<br />
Gen.Orph 
Tel: +33 (0)1 47 71 04 e-mail: contact@gen-orph.com 
Ireland<br />
Gen.Orph 
Tel : +33 (0)1 47 71 04 email: contact@gen-orph.com </p>
<p>Slovenija<br />
Gen.Orph 
Tel: +33 (0)1 47 71 04 email: contact@gen-orph.com </p>
<p>sland<br />
Gen.Orph 
S mi: +33 (0)1 47 71 04 e-mail : contact@gen-orph.com </p>
<p>Slovensk  republika<br />
Gen.Orph 
Tel: +33 (0)1 47 71 04 email: contact@gen-orph.com </p>
<p>Italia<br />
Biovalley Investments Partner S.r.l. 
Tel: +39 040 899 2e.mail: info@biovalleyinvestmentspartner.it </p>
<p>Suomi/Finland<br />
Gen.Orph 
Puh/Tel : +46 (0)8 21 54 e-mail: pharmacovigilance.SE@propharmagroup.com </p>
<p>Gen.Orph 
 : +33 (0)1 47 71 04 email: contact@gen-orph.com </p>
<p>Sverige<br />
Gen.Orph 
Tel: +46 (0)8 21 54 e-mail : pharmacovigilance.SE@propharmagroup.com </p>
<p>Latvija<br />
Gen.Orph 
Tel: +33 (0)1 47 71 04 e-mail : contact@gen-orph.com 
United Kingdom<br />
Gen.Orph 
Tel: +33 (0)1 47 71 04 email: contact@gen-orph.com </p>
<p>This leaflet was last revised in {month YYYY}. </p>
<p>Detailed information on this medicine is available on the European Medicines Agency web site: </p> </div>"""      



Instance: composition-da-e8ab7070a1e099803634040c1dcebc5b
InstanceOf: CompositionUvEpi
Title: "Composition for miglustat Package Leaflet"
Description:  "Composition for miglustat Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "EU/1/17/1232/001"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mpe8ab7070a1e099803634040c1dcebc5b)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - miglustat"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional

  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>unavailable</div>"""
  * emptyReason = http://terminology.hl7.org/CodeSystem/list-empty-reason#unavailable   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>unavailable</div>"""
  * emptyReason = http://terminology.hl7.org/CodeSystem/list-empty-reason#unavailable   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen 
1. Virkning og anvendelse 
2. Det skal De vide, før De begynder at tage Miglustat Gen.Orph 
3. Sådan skal De tage Miglustat Gen.Orph 
4. Bivirkninger 
5. Opbevaring 
6. Pakningsstørrelser og yderligere oplysninger </p> </div>"""   
          

* section[=].section[+]
  * title =  "1. What miglustat is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What miglustat is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Miglustat Gen.Orph indeholder det aktive stof miglustat, som tilhører en gruppe af lægemidler, som 
påvirker stofskiftet. Det anvendes til behandling af to tilstande: </p>
<ul>
<li>Miglustat Gen.Orph anvendes til behandling af let til moderat Gauchers sygdom, type 1, hos 
voksne. </li>
</ul>
<p>Ved Gauchers sygdom, type 1 er der et stof kaldet glucosylceramid, som ikke fjernes fra kroppen. Det 
ophobes i visse celler i kroppens immunsystem. Dette kan medføre forstørrelse af lever og milt, 
forandringer i blodet og knoglesygdom.  </p>
<p>Den almindelige behandling af Gauchers sygdom, type 1 er enzymsubstitutionsterapi. Miglustat 
Gen.Orph anvendes kun, når en patient anses for uegnet til behandling med enzymsubstitutionsterapi. </p>
<ul>
<li>Miglustat Gen.Orph anvendes også til behandling af fremadskridende neurologiske 
symptomer ved Niemann-Picks sygdom, type C, hos voksne og børn. </li>
</ul>
<p>Hvis De har Niemann-Picks sygdom, type C, ophobes fedt f.eks. glycosphingolipider i cellerne i Deres 
hjerne. Det kan resultere i forstyrrelser i neurologiske funktioner som f.eks. langsomme 
øjenbevægelser, balance, synkning og hukommelse samt i krampeanfald. </p>
<p>Miglustat Gen.Orph virker ved at hæmme et enzym, som kaldes ’glucosylceramidsyntase’, som er 
ansvarlig for det første trin i omdannelsen af de fleste glycosphingolipider. </p> </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take miglustat"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take miglustat"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag ikke Miglustat Gen.Orph 
- hvis De er allergisk over for miglustat eller et af de øvrige indholdsstoffer i Miglustat Gen.Orph 
(angivet i punkt 6). </p>
<p>Advarsler og forsigtighedsregler 
Kontakt lægen eller apotekspersonalet, før De tager Miglustat Gen.Orph, 
- hvis De lider af en nyresygdom 
- hvis De lider af en leversygdom </p>
<p>Deres læge vil gennemføre følgende tests, før og under behandling med Miglustat Gen.Orph:</p>
<ul>
<li>en undersøgelse for at kontrollere nerverne i Deres arme og ben </li>
<li>måling af vitamin B12-niveauerne </li>
<li>kontrollere Deres vækst, hvis De er barn eller ung med Niemann-Picks sygdom, type C </li>
<li>kontrollere antallet af blodplader </li>
</ul>
<p>Årsagen til disse prøver er, at visse patients har snurren eller følelsesløshed i hænder og fødder, eller 
taber i vægt, når de tager Miglustat Gen.Orph. Prøverne vil hjælpe lægen til at beslutte, om disse 
virkninger skyldes Deres sygdom eller eksisterende tilstande eller er bivirkninger af Miglustat 
Gen.Orph (se punkt 4 for nærmere oplysninger). </p>
<p>Hvis De har diarré, vil Deres læge måske bede Dem om følgende: At De ændrer Deres kost for at 
reducere indtagelsen af lactose og kulhydrater såsom sukrose (sukker), at De ikke tager Miglustat 
Gen.Orph sammen med måltider, eller at De nedsætter Deres dosis midlertidigt. I nogle tilfælde vil 
lægen ordinere et lægemiddel mod diarré, for eksempel loperamid. Henvend Dem til Deres læge, hvis 
Deres diarré ikke reagerer på disse foranstaltninger, eller hvis De har andre maveproblemer. Hvis det er 
tilfældet vil Deres læge muligvis beslutte, at der skal gennemføres flere undersøgelser. </p>
<p>Mandlige patienter bør anvende pålidelige præventionsmidler under behandling med Miglustat 
Gen.Orph og i 3 måneder efter, at behandlingen er afsluttet. </p>
<p>Børn og unge 
Giv ikke denne medicin til børn og unge (under 18 år) med Gauchers sygdom, type 1, da det ikke vides, 
om den virker. </p>
<p>Brug af anden medicin sammen med Miglustat Gen.Orph 
Fortæl det altid til lægen eller apoteketspersonalet, hvis De tager anden medicin, for nylig har taget 
anden medicin eller planlægger at tage anden medicin. </p>
<p>Fortæl det til lægen, hvis De tager lægemidler, der indeholder imiglucerase, som nogle gange bruges 
samtidigt med Miglustat Gen.Orph. Imiglucerase kan nedsætte mængden af Miglustat Gen.Orph i 
kroppen. </p>
<p>Graviditet, amning og frugtbarhed 
De må ikke tage Miglustat Gen.Orph, hvis De er gravid, eller hvis De overvejer at blive gravid. Deres 
læge kan give Dem yderligere oplysninger. De skal benytte effektiv prævention, mens De tager 
Miglustat Gen.Orph. De må ikke amme, mens De tager Miglustat Gen.Orph. </p>
<p>Mænd skal anvende sikker prævention under behandlingen og i 3 måneder efter, behandlingen med 
Miglustat Gen.Orph er afsluttet. </p>
<p>Hvis De er gravid eller ammer, har mistanke om, at De er gravid, eller planlægger at blive gravid, skal 
De spørge Deres læge eller apotekspersonalet til råds, før De tager dette lægemiddel. </p>
<p>Trafik- og arbejdssikkerhed 
Miglustat Gen.Orph kan forårsage svimmelhed. Lad være med at køre bil eller arbejde med værktøj 
eller maskiner, hvis De føler Dem svimmel. </p>
<p>Miglustat Gen.Orph indeholder natrium 
Dette lægemiddel indeholder mindre end 1 mmol (23 mg) natrium pr. hård kapsel, dvs. det er i det 
væsentlige natriumfrit. </p> </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take miglustat"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take miglustat"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag altid lægemidlet nøjagtigt efter lægens anvisning. Er De i tvivl, så spørg lægen eller 
apotekspersonalet. </p>
<ul>
<li>
<p>Ved Gauchers sygdom, type 1: Til voksne er den sædvanlige dosis én kapsel (100 mg) tre 
gange dagligt (morgen, eftermiddag og aften). Det vil sige maksimalt tre kapsler (300 mg) om 
dagen. </p>
</li>
<li>
<p>Ved Niemann-Picks sygdom, type C: Til voksne og unge (over 12 år) er den sædvanlige dosis 
på to kapsler (200 mg) tre gange dagligt (morgen, eftermiddag og aften). Det vil sige maksimalt 
seks kapsler (600 mg) om dagen. </p>
</li>
</ul>
<p>Lægen vil tilpasse dosis hos børn under 12 år med Niemann-Picks sygdom, type C. </p>
<p>Hvis De har problemer med Deres nyrer, skal De muligvis starte med en lavere dosis. Hvis De lider af 
diarré under behandlingen med Miglustat Gen.Orph, vil Deres læge muligvis sætte Deres dosis ned, 
f.eks. til én kapsel (100 mg) én eller to gange dagligt (se punkt 4). Deres læge vil fortælle Dem, hvor 
længe behandlingen skal vare. </p>
<p>Miglustat Gen.Orph kan tages sammen med eller uden mad. De skal synke kapslen hel med et glas 
vand. </p>
<p>Hvis De har taget for mange Miglustat Gen.Orph 
Hvis De tager flere kapsler, end De har fået besked på, skal De straks søge læge. Miglustat Gen.Orph er 
blevet anvendt i kliniske forsøg med doser op til 3 000 mg: Dette medførte et fald i antallet af hvide 
blodlegemer og andre bivirkninger svarende til dem, der er beskrevet i punkt 4. Hvis De har glemt at tage Miglustat Gen.Orph 
Tag den næste kapsel til sædvanlig tid. De må ikke tage en dobbeltdosis som erstatning for den glemte 
dosis.  </p>
<p>Hvis De holder op med at tage Miglustat Gen.Orph 
Stop ikke med at tage Miglustat Gen.Orph uden at rådføre Dem med lægen. </p>
<p>Spørg lægen eller apotekspersonalet, hvis der er noget De er i tvivl om. </p> </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel kan som al anden medicin give bivirkninger, men ikke alle får bivirkninger.  </p>
<p>Mest alvorlige bivirkninger:<br />
Nogle patienter har haft snurren eller følelsesløshed i hænder og fødder (almindelig bivirkning). 
Dette kan være tegn på perifer neuropati, som skyldes bivirkninger af Miglustat Gen.Orph, eller det kan 
være på grund af eksisterende lidelser. Deres læge vil gennemføre nogle prøver før og under 
behandling med Miglustat Gen.Orph for at bedømme dette (se punkt 2).  </p>
<p>Hvis De får nogle af disse bivirkninger, skal De søge rådgivning hos lægen så hurtigt som muligt. </p>
<p>Hvis De får en let rysten, sædvanligvis af hænderne, skal De søge rådgivning hos lægen så hurtigt 
som muligt. Denne rysten forsvinder ofte, uden at det er nødvendigt at stoppe behandlingen. Af og til 
vil det være nødvendigt for lægen at nedsætte dosis eller stoppe behandlingen med Miglustat Gen.Orph 
for at stoppe denne rysten. </p>
<p>Meget almindelige bivirkninger (kan forekomme hos flere end 1 ud af 10 behandlede) 
De almindeligste bivirkninger er diarré, flatulens (luft i maven), mavesmerter, vægttab og nedsat 
appetit.  </p>
<p>Hvis De taber i vægt, når De starter behandling med Miglustat Gen.Orph, skal De ikke blive 
bekymret. Normalt ophører vægttabet ved fortsat behandling. </p>
<p>Almindelige bivirkninger (kan forekomme hos op til 1 ud af 10 behandlede)<br />
Almindelige bivirkninger af behandlingen omfatter hovedpine, svimmelhed, paræstesi (snurrende 
fornemmelse eller følelsesløshed), koordinationsforstyrrelser, hypoæstesi (nedsat følesans), 
fordøjelsesbesvær (halsbrand), kvalme (utilpashed), forstoppelse og opkastning, hævelse eller ubehag i 
underlivet (maven) og trombocytopeni (nedsat antal blodplader). De neurologiske symptomer og 
trombocytopeni kan skyldes den underliggende sygdom. </p>
<p>Andre mulige bivirkninger er muskelkramper eller -svaghed, træthed, kulderystelser og utilpashed, 
depression, søvnbesvær, glemsomhed og nedsat lyst til sex (libido). </p>
<p>De fleste patienter oplever en eller flere af disse bivirkninger, i reglen i starten af behandlingen eller 
med mellemrum under behandlingen. De fleste tilfælde er lette og forsvinder ret hurtigt. Hvis nogle af 
disse bivirkninger giver anledning til problemer, skal De rådføre Dem med lægen. Han eller hun kan 
nedsætte Deres dosis af Miglustat Gen.Orph eller anbefale anden medicin, der kan hjælpe med at 
kontrollere bivirkningerne. </p>
<p>Indberetning af bivirkninger 
Hvis De oplever bivirkninger, bør De tale med Deres læge eller apotekspersonalet. Dette gælder 
også mulige bivirkninger, som ikke er medtaget i denne indlægsseddel. De eller Deres pårørende kan 
også indberette bivirkninger direkte til Lægemiddelstyrelsen via det nationale rapporteringssystem 
anført i Appendiks V. Ved at indrapportere bivirkninger kan De hjælpe med at fremskaffe mere 
information om sikkerheden af dette lægemiddel. </p> </div>"""      
        
* section[=].section[+]
  * title = "5. How to store miglustat"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store miglustat"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opbevar lægemidlet utilgængeligt for børn. </p>
<p>Brug ikke lægemidlet efter den udløbsdato, der står på pakningen efter Exp. Udløbsdatoen er den sidste 
dag i den nævnte måned. </p>
<p>Dette lægemiddel kræver ingen særlige forholdsregler vedrørende opbevaringen.  </p>
<p>Spørg på apotekspersonalet, hvordan De skal bortskaffe medicinrester. Af hensyn til miljøet må De 
ikke smide medicinrester i afløbet, toilettet eller skraldespanden. </p> </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Miglustat Gen.Orph indeholder: </p>
<p>Aktivt stof: miglustat 100 mg. </p>
<p>Øvrige indholdsstoffer: 
Natriumstivelsesglycolat (type A)<br />
Povidon (K30) 
Magnesiumstearat 
Gelatine<br />
Titandioxid (E171) 
Se punkt 2 "Miglustat Gen.Orph indeholder natrium". 
Udseende og pakningsstørrelser 
Miglustat Gen.Orph 100 mg fås som hårde kapsler med en hvid uigennemsigtig overdel og underdel; 
kapslerne er fremstillet af hård gelatine, og de har str. 4 og en længde på 14 mm. 
Pakningsstørrelse på 84 hårde kapsler i ikke-perforeret blister og 84x1 hårde kapsler i perforeret 
enkeltdosisblister. </p>
<p>Ikke alle pakningsstørrelser er nødvendigvis markedsført. </p>
<p>Indehaver af markedsføringstilladelsen: </p>
<p>Gen.Orph 
185 Bureaux de la Colline 
92213 Saint Cloud Cedex 
Frankrig </p>
<p>Fremstillere: 
Delpharm Reims 
10 rue Colonel Charbonneaux 
51100 Reims 
Frankrig </p>
<p>eller </p>
<p>Centre Lab 
ZA Granderaie 
23000 Guéret 
Frankrig </p>
<p>Hvis De ønsker yderligere oplysninger om dette lægemiddel, skal De henvende Dem til den lokale 
repræsentant for indehaveren af markedsføringstilladelsen. </p>
<p>België/Belgique/Belgien<br />
Gen.Orph<br />
Tél/Tel: +32 (0)496 85 87 e-mail: reg@studiopharma.be  </p>
<p>Lietuva<br />
Gen.Orph 
Tel: +33 (0)1 47 71 04 e-mail: contact@gen-orph.com </p>
<p>България<br />
Диакомерс ЕООД 
Тел.: +359 2 807 50 Е-mail: diacommerce@diacommerce.bg </p>
<p>Luxembourg/Luxemburg<br />
Gen.Orph 
Tél/Tel.: +32 (0)496 85 87 email: reg@studiopharma.be </p>
<p>Česká republika<br />
Gen.Orph 
Tel: +33 (0)1 47 71 04 e-mail: contact@gen-orph.com 
Magyarország<br />
HMS Pharma Kft. 
Tel.: +36 30 375 8e-mail: pharmacovigilance@hmspharma.com<br />
Danmark<br />
Gen.Orph 
Tlf: +46 (0)8 21 54 e-mail: pharmacovigilance.SE@propharmagroup.com </p>
<p>Malta<br />
Gen.Orph 
Tel: +33 (0)1 47 71 04 e-mail: contact@gen-orph.com 
Deutschland<br />
Gen.Orph 
Tel: +49 30 8560687email: pharmacovigilance.DE@propharmagroup.com </p>
<p>Nederland<br />
Gen.Orph 
Tel: +32 (0)496 85 87 e-mail: reg@studiopharma.be  </p>
<p>Eesti<br />
Gen.Orph 
Tel: +33 (0)1 47 71 04 email: contact@gen-orph.com </p>
<p>Norge<br />
Gen.Orph 
Tlf: +46 (0)8 21 54 e-mail: pharmacovigilance.SE@propharmagroup.com </p>
<p>Ελλάδα<br />
Gen.Orph 
Τηλ: +33 (0)1 47 71 04 email: contact@gen-orph.com </p>
<p>Österreich<br />
Gen.Orph 
Tel : +33 (0)1 47 71 04 e-mail: contact@gen-orph.com 
España<br />
Pharma International S.A. 
Tel: +34 915 635 e-mail: farmacovigilancia@pharmaintl.net </p>
<p>Polska<br />
Gen.Orph 
Tel.: +33 (0)1 47 71 04 e-mail: contact@gen-orph.com </p>
<p>France<br />
Gen.Orph 
Tél.: +33 (0)1 47 71 04 e-mail : contact@gen-orph.com </p>
<p>Portugal<br />
Biojam, S.A. 
Tel:  +351 212 697 e-mail: farmacovigilancia@phagecon.pt </p>
<p>Hrvatska<br />
Gen.Orph 
Tel: +33 (0)1 47 71 04 e-mail : contact@gen-orph.com </p>
<p>România<br />
Gen.Orph 
Tel: +33 (0)1 47 71 04 e-mail: contact@gen-orph.com 
Ireland<br />
Gen.Orph 
Tel : +33 (0)1 47 71 04 email: contact@gen-orph.com </p>
<p>Slovenija<br />
Gen.Orph 
Tel: +33 (0)1 47 71 04 email: contact@gen-orph.com </p>
<p>Ísland<br />
Gen.Orph 
Sími: +33 (0)1 47 71 04 e-mail : contact@gen-orph.com </p>
<p>Slovenská republika<br />
Gen.Orph 
Tel: +33 (0)1 47 71 04 e-mail: contact@gen-orph.com 
Italia<br />
Biovalley Investments Partner S.r.l. 
Tel: +39 040 899 2e.mail:info@biovalleyinvestmentspartner.it </p>
<p>Suomi/Finland<br />
Gen.Orph 
Puh/Tel : +46 (0)8 21 54 e-mail : pharmacovigilance.SE@propharmagroup.com </p>
<p>Κύπρος<br />
Gen.Orph 
Τηλ: +33 (0)1 47 71 04 email: contact@gen-orph.com </p>
<p>Sverige<br />
Gen.Orph 
Tel: +46 (0)8 21 54 e-mail : pharmacovigilance.SE@propharmagroup.com </p>
<p>Latvija<br />
Gen.Orph 
Tel: +33 (0)1 47 71 04 e-mail : contact@gen-orph.com 
United Kingdom<br />
Gen.Orph 
Tel: +33 (0)1 47 71 04 e-mail: contact@gen-orph.com </p>
<p>Denne indlægsseddel blev senest ændret: {måned ÅÅÅÅ} </p>
<p>De kan finde yderligere oplysninger om Miglustat Gen.Orph på Det Europæiske Lægemiddelagenturs 
hjemmeside: http://www.ema.europa.eu. Der er også links til andre websteder om sjældne sygdomme 
og om, hvordan de behandles. </p> </div>"""      





                    
Instance: bundlepackageleaflet-en-e8ab7070a1e099803634040c1dcebc5b
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for miglustat Package Leaflet for language en"
Description: "ePI document Bundle for miglustat Package Leaflet for language en"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-e8ab7070a1e099803634040c1dcebc5b"
* entry[0].resource = composition-en-e8ab7070a1e099803634040c1dcebc5b

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mpe8ab7070a1e099803634040c1dcebc5b"
* entry[=].resource = mpe8ab7070a1e099803634040c1dcebc5b
                            
                    
Instance: bundlepackageleaflet-da-e8ab7070a1e099803634040c1dcebc5b
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for miglustat Package Leaflet for language da"
Description: "ePI document Bundle for miglustat Package Leaflet for language da"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-e8ab7070a1e099803634040c1dcebc5b"
* entry[0].resource = composition-da-e8ab7070a1e099803634040c1dcebc5b

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mpe8ab7070a1e099803634040c1dcebc5b"
* entry[=].resource = mpe8ab7070a1e099803634040c1dcebc5b
                            
                    



Instance: mpe8ab7070a1e099803634040c1dcebc5b
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product Miglustat Gen.Orph 100 mg hard capsules"
Description: "Miglustat Gen.Orph 100 mg hard capsules"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "EU/1/17/1232/001"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"



* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"

* name
  * productName = "Miglustat Gen.Orph 100 mg hard capsules"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#EU "EU"
    * jurisdiction = urn:iso:std:iso:3166#EU "EU"
    * language = urn:ietf:bcp:47#en  "en"



RuleSet: e8ab7070a1e099803634040c1dcebc5bListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "miglustat"

* status = #current
* mode = #working

* title = "List of all ePIs associated with miglustat"

* subject = Reference(mpe8ab7070a1e099803634040c1dcebc5b)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#miglustat "miglustat"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-e8ab7070a1e099803634040c1dcebc5b) // miglustat en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-e8ab7070a1e099803634040c1dcebc5b) // miglustat da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-e8ab7070a1e099803634040c1dcebc5b
InstanceOf: List

* insert e8ab7070a1e099803634040c1dcebc5bListRuleset
    